{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073089","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.745833+00:00","generated_at":"2026-05-17T17:54:58.881741+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio posts $24.5M net loss, CEO replaced; INKmune trial meets endpoints","bullets":["Net loss $24.5M in Q2 2025 vs $9.7M in Q2 2024; includes $16.5M impairment of in-process R&D intangibles.","CEO RJ Tesi retires; David Moss appointed President & CEO; Cory Ellspermann Interim CFO.","INKmune CaRe PC trial in mCRPC met primary safety and secondary endpoints; trial closed to enrollment.","XPro MINDFuL trial missed primary cognitive endpoints overall; positive trends in enriched biomarker subset.","Cash $33.4M as of June 30; completed $19M registered direct offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073089","json":"https://secwatch.observer/filing/0001213900-25-073089.json","markdown":"https://secwatch.observer/filing/0001213900-25-073089.md","text":"https://secwatch.observer/filing/0001213900-25-073089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/0001213900-25-073089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/ea0251921-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:54:58.881741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}